Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 455-461

  Huang, K F ^a,b   Huang, X P ^a   Xiao, G Q ^a   Yang, H Y ^a   Lin, J S ^a,c   Diao, Y ^a  

^a HUAQIAO UNIVERSITY   (China)

^b Xiamen Medicine Research Institute   (China)

^c INVERMAY AGRICULTURAL CENTRE   (New Zealand)

Author keywords

Angiogenesis; Kallistatin; NF B; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMETASTATIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT HUMAN KALLISTATIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; KALLISTATIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EMBRYO; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHICK EMBRYO; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MCF-7 CELLS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; SERPINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901587087     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.005     Document Type: Article

References (38)

1. Zhou G.X., Chao L., Chao J. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 1992, 267:25873-25880.
2. Chai K.X., Chen L.M., Chao J., Chao L. Kallistatin: a novel human serine proteinase inhibitor-molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem 1993, 268:24498-24505.
3. Wang C.R., Chen S.Y., Wu C.L., Liu M.F., Jin Y.T., Chao L., et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum 2005, 52:1319-1324.
4. Zhu B., Lu L., Cai W., Yang X., Li C., Yang Z., et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007, 6:3297-3306.
5. Lu L., Yang Z., Zhu B., Fang S., Yang X., Cai W., et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by antiangiogenic activity. Cancer Lett 2007, 257:97-106.
6. Miao R.Q., Agata J., Chao L., Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002, 100:3245-3252.
7. Tse L.Y., Sun X.Y., Jiang H.C., Dong X.S., Fung P.W.C., Farzaneh F., et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med 2008, 508-517.
8. Folkman J., Cole P., Zimmerman S. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966, 164:491-502.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
10. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001, 33:357-369.
11. Scappaticci F.A. Mechanisms and future directions for angiogenesis based cancer therapies. J Clin Oncol 2002, 20:3906-3927.
12. Clark E.R., Clark E.L. Microscopic observations on the growth of blood capillaries in the living mammal. Am J Anat 1939, 64:251-301.
13. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
14. Milkiewicz M., Ispanovic E., Doyle J.L., Haas T.L. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006, 38:333-357.
15. Tsuzuki T., Shibata A., Kawakami Y., Nakagawa K., Miyazawa T. Conjugated eicosapentaenoic acid inhibits vascular endothelial growth factor-induced angiogenesis by suppressing the migration of human umbilical vein endothelial cells. J Nutr 2007, 137:641-646.
16. Takekoshi K., Isobe K., Yashiro T., Hara H., Ishii K., Kawakami Y., et al. Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 2004, 74:863-871.
17. Arsura M., Cavin L.G. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005, 229:157-169.
18. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
19. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8:837-848.
20. Hayden M.S., Ghosh S. NF-kappaB in immunobiology. Cell Res 2011, 21:223-244.
21. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
22. Lu N., Yang Y., You Q.D., Ling Y., Gao Y., Gu H.Y., et al. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 2007, 258:80-89.
23. Berger A.C., Wang X.Q., Zalatoris A., Cenna J., Watson J.C. A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot. Microvasc Res 2004, 68:179-187.
24. Sung B., Pandey M.K., Ahn K.S., Yi T., Chaturvedi M.M., Liu M., et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 2008, 111:4880-4891.
25. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995, 73:333-346.
26. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
27. National Cancer Institute at the National Institutes of Health, FDA Approval Summary for Bevacizumab. Accessed on November 10, 2008:. http://www.cancer.gov/cancertopics/durginfo/fda-bevacizumab.
28. National Cancer Institute at the National Institutes of Health, FDA Approval Summary for Sorafenib Tosylate. Accessed on: November 10, 2008:. http://www.cancer.gov/cancertopics/durginfo/fda-sorafenibtosylate.
29. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
30. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896.
31. Christensen J.G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007, 18:3-10.
32. Gao G.Q., Shao C.K., Zhang S.X., Dudley A., Fant J., Ma J.X. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 2003, 46:689-698.
33. Chen L.M., Chao L., Chao J. Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci 1997, 60:1431-1435.
34. Cao Y.H. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001, 33:357-369.
35. Zakarija A., Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005, 17:578-583.
36. Wu Y., Zhong Z., Huber J., Bassi R., Finnerty B., Corcoran E., et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006, 21:6573-6584.
37. Itoh Y., Nagase H. Matrix metalloproteinases in cancer. Essays Biochem 2002, 38:21-36.
38. Bernhard E.J., Gruber S.B., Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A 1994, 91:4293-4297.